ANTIVIRAL RESEARCH, published by Elsevier, stands at the forefront of the study of antiviral agents and therapy, with a dedicated focus on advancing the understanding of viral infections and their mechanisms. The journal is recognized within the top tier of academic publications, belonging to the prestigious Q1 category in both Pharmacology and Virology as of 2023, ranking 12th out of 313 in Pharmacology and 11th out of 80 in Virology according to Scopus metrics, reflecting its significant impact in the field. With a long-standing history since its inception in 1959, it continues to serve as an essential platform for researchers and health professionals alike, sharing critical findings that drive innovation in antiviral therapeutics. Although it does not currently offer open access options, the journal’s rigorous peer-review process ensures that every published article meets high academic standards, providing invaluable insights for those dedicated to enhancing public health through virology research.

ACTA VIROLOGICA, a key journal in the field of virology and infectious diseases, is published by FRONTIERS MEDIA SA in Slovakia, serving the global scientific community with groundbreaking research since its inception in 1957. This esteemed journal, identified by ISSN 0001-723X and E-ISSN 1336-2305, provides a platform for rigorous peer-reviewed articles that contribute significantly to our understanding of viral pathogens and their implications in medicine. Positioned within the Q3 category for both Infectious Diseases and Miscellaneous Medicine, and a Q4 category for Virology in 2023, ACTA VIROLOGICA offers crucial insights into the evolving landscape of virology research. With its robust accessibility options, this journal appeals to a diverse readership, including researchers, healthcare professionals, and students, fostering a collaborative environment to advance the field of virology. The editorial objective is to enhance the catalog of knowledge pertaining to viruses, promoting innovative approaches in prevention, diagnostics, and treatment. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE CH-1015, SWITZERLAND, ACTA VIROLOGICA continues to be a vital resource in the collective efforts to combat viral disease challenges.

VIRUS GENES is an esteemed journal published by Springer, dedicated to advancing our understanding of virology and its related fields, including genetics, molecular biology, and immunology. With a publication history that spans from 1987 to 2024, this journal provides researchers and professionals with a platform to disseminate high-quality, peer-reviewed articles that explore the intricacies of viral genetics and their implications in health and disease. With an impact factor placing it in the Q3 quartile across multiple categories in 2023, including Genetics and Virology, VIRUS GENES serves as a crucial resource for academics seeking to stay at the forefront of viral research. Its commitment to showcasing innovative research makes it an invaluable asset for students and professionals aiming to deepen their knowledge in the rapidly evolving landscape of virology. Although currently not offering Open Access, the journal ensures wide accessibility through institutional subscriptions, thereby playing a vital role in the collaboration between scientists globally.

Tumour Virus Research, an esteemed journal published by Elsevier, serves as a vital resource in the fields of cancer research, infectious diseases, and virology. With an impact factor reflective of its influence and recognized as a Q2 journal in multiple categories as of 2023, it rigorously presents high-impact research dedicated to the understanding of viral pathogens in tumorigenesis. Since its transition to an Open Access model in 2021, the journal has enhanced accessibility, empowering researchers and the academic community globally to explore cutting-edge findings. The journal covers a broad scope, encompassing the intricate interactions between viruses and cancer biology, which is crucial for developing novel therapeutic strategies. With a commitment to advancing scientific knowledge, Tumour Virus Research welcomes submissions that push the boundaries of current understanding and contribute to the ongoing battle against virus-mediated cancers, making it an indispensable publication for professionals, researchers, and students in the field.

Retrovirology is a prominent open-access journal published by BMC since 2004, dedicated to the field of retroviral research. With a strong focus on advancing knowledge in both infectious diseases and virology, this interdisciplinary journal has achieved a commendable ranking of Q2 in its respective categories as of 2023, reflecting its significant contribution to the scientific community. Hosted in the United Kingdom, Retrovirology serves a global audience of researchers, professionals, and students, making vital research accessible to all without barriers. The journal's emphasis on high-quality peer-reviewed articles supports the dissemination of groundbreaking findings that could shape the future of virology and related fields. With an impressive Scopus ranking, including a percentile of 65th in Medicine: Infectious Diseases, it stands out as a valuable resource for those committed to understanding and combating viral diseases. Retrovirology continues to be an essential platform for innovative research, with its open-access model ensuring that transformational science reaches the widest possible audience.

The JOURNAL OF GENERAL VIROLOGY, published by the Microbiology Society, is a premier academic journal dedicated to advancing the field of virology. Established in 1967, this influential journal covers a wide spectrum of research from basic virology to applied studies, serving as a vital resource for researchers, professionals, and students alike. With its ISSN 0022-1317 and E-ISSN 1465-2099, the journal is recognized for its rigorous peer-review process and high-quality publications, attaining a commendable Q2 ranking in the Virology category for 2023. The journal's focus on disseminating innovative findings and fostering critical discussions contributes significantly to the understanding of viral mechanisms, disease processes, and potential therapeutic strategies. Although it does not currently offer Open Access options, the journal remains accessible to the academic community, with a strong commitment to supporting virology research globally. As part of Scopus' top-tier rankings, illustrating its impact within the category of Immunology and Microbiology, the JOURNAL OF GENERAL VIROLOGY continues to play a pivotal role in shaping the future of virological science.

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

Future Virology, published by Future Medicine Ltd, is an essential journal dedicated to advancing the understanding of virology in the contemporary scientific landscape. With an ISSN of 1746-0794 and an E-ISSN of 1746-0808, this journal serves as a platform for researchers and practitioners in the field to publish high-quality, peer-reviewed articles that explore novel discoveries, innovative therapeutic strategies, and the implications of viral research on global health. Operating from the United Kingdom and maintaining a commitment to rigorous scientific inquiry, Future Virology is categorized in the Q4 Quartile for Virology according to the latest Scopus rankings, with a position of Rank #48/80 and a percentile of 40th in the Virology category. Although it currently does not offer open access, the journal strives to disseminate critical insights that benefit a wide range of professionals, researchers, and students engaged in virology and related fields. By bridging the gap between basic research and practical applications, Future Virology plays a crucial role in fostering innovation and collaboration in the ever-evolving virology landscape.

The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.

Virology Journal, published by BMC, stands as a prominent open-access platform since 2004, dedicated to advancing the field of virology and infectious diseases. With its E-ISSN: 1743-422X, this journal is based in the United Kingdom and strives to disseminate high-quality research that enhances our understanding of viral pathogens and their interactions with hosts. Recognized with a Q1 classification in the category of Infectious Diseases and a Q2 in Virology for 2023, Virology Journal holds significant standing in the academic community, ranking #82/344 in Medicine - Infectious Diseases and #26/80 in Immunology and Microbiology - Virology. Its commitment to open access ensures that cutting-edge research is freely available to researchers, professionals, and students worldwide, fostering collaboration and innovation in the fight against viral diseases. The journal aims to publish original research articles, reviews, and commentaries that will stimulate discourse and spark new ideas within the virology community.